Developing proprietary plant-derived biomolecules to prevent metabolic diseases. Initial pipeline includes 5+ products targeting prediabetes/T2D, NAFL/NASH, hypercholesterolemia, and obesity. Lead program VALEDIA®, targeting the unaddressed prediabetes market, recently reported positive Ph 2a data for prediabetes. VALEDIA® significantly reduced fasting blood glucose levels, compared to the placebo, after 6 months (p<0.05).
Phase l or ll
Cardiovascular, Diabetes, Metabolic Disorders
12F rue Paul Vatine
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by